---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024960"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:47.418561+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Moleculin preclin data: Annamycin shows efficacy in liver cancers; AML readout H2 2025

## Summary
- Annamycin demonstrated anti-tumor activity in orthotopic HCC models, colorectal liver metastases, and PDAC liver metastases.
- Preclinical data show targeted organ accumulation (liver, spleen, lungs, pancreas) vs doxorubicin; no cardiotoxicity seen.
- Prior clinical data: 32 of 42 subjects received >FDA lifetime max anthracycline without cardiotoxicity.
- Preliminary data readout for Annamycin in AML expected in second half of 2025.
- Data presented at Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center.

## SEC filing metadata
- accession: 0001437749-25-024960
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/0001437749-25-024960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774925024960/mbrx20250805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024960
- JSON: https://secwatch.observer/filing/0001437749-25-024960.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024960.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.